# PCYOX1

## Overview
PCYOX1 is a gene that encodes the enzyme prenylcysteine oxidase 1, a flavin adenine dinucleotide (FAD)-dependent thioether monooxygenase. This enzyme is primarily involved in the degradation of prenylated proteins, which are crucial for various cellular functions due to their isoprenoid modifications. Prenylcysteine oxidase 1 catalyzes the oxidative cleavage of prenylcysteine residues, facilitating the turnover of these proteins and contributing to cellular processes such as signaling, metabolism, and protein degradation (Osada2018Prenylcysteine). The enzyme is predominantly located in lysosomes and plasma lipoproteins, where it plays a role in generating reactive oxygen species, thus influencing oxidative stress and related pathologies like atherosclerosis and thrombosis (Banfi2022Prenylcysteine; Osada2018Prenylcysteine). PCYOX1's involvement in these processes underscores its significance in cardiovascular and metabolic health, making it a potential target for therapeutic interventions (Banfi2023Prenylcysteine; Banfi2021Prenylcysteine).

## Function
Prenylcysteine oxidase 1 (PCYOX1) is an enzyme that plays a crucial role in the degradation of prenylated proteins, which are proteins modified with isoprenoid groups such as farnesyl or geranylgeranyl. This modification is essential for the proper localization and function of these proteins within the cell. PCYOX1 catalyzes the oxidative cleavage of prenylcysteine residues, releasing free cysteine and an isoprenoid aldehyde, such as farnesal, as byproducts. This process is considered the final step in the turnover of prenylated proteins, which constitute about 2% of all cellular proteins (Osada2018Prenylcysteine).

PCYOX1 is a flavin adenine dinucleotide (FAD)-dependent thioether monooxygenase primarily located in lysosomes and plasma lipoproteins, such as very low-density lipoproteins (VLDL) and low-density lipoproteins (LDL) (Osada2018Prenylcysteine). The enzyme's activity generates hydrogen peroxide, a reactive oxygen species, which can contribute to oxidative stress and has implications in atherogenesis and thrombosis (Banfi2022Prenylcysteine; Osada2018Prenylcysteine). PCYOX1 is also involved in various cellular processes, including cell signaling, metabolism, and protein degradation, and acts as a co-chaperone in the ubiquitination machinery (Osada2018Prenylcysteine). Its activity is regulated by post-translational modifications and influenced by dietary and hormonal factors (Osada2018Prenylcysteine).

## Clinical Significance
Alterations in the expression or function of the PCYOX1 gene have been implicated in several diseases, particularly those related to cardiovascular health and metabolic disorders. PCYOX1 is involved in the pathogenesis of atherosclerosis and atherothrombosis, where it contributes to oxidative stress by producing hydrogen peroxide, a reactive oxygen species (Banfi2022Prenylcysteine). This oxidative stress is linked to the oxidation of apolipoprotein B100-containing lipoproteins, promoting the development of atherosclerotic lesions (Banfi2021Prenylcysteine). Studies in mice have shown that PCYOX1 deficiency can retard atheroprogression, reduce lesion vulnerability, and lower plasma lipid levels, suggesting that PCYOX1 could be a target for preventing atherosclerosis-related diseases (Banfi2021Prenylcysteine).

PCYOX1 also plays a role in thrombosis, where its absence in knockout mice leads to reduced platelet activation and aggregation, indicating its potential as a target for antithrombotic therapies (Banfi2022Prenylcysteine). Furthermore, PCYOX1 is implicated in adipogenesis and metabolic syndrome, with its deficiency resulting in reduced adipose tissue and inflammation, highlighting its role in obesity-related conditions (Banfi2023Prenylcysteine). These findings suggest that PCYOX1 is a significant factor in cardiovascular and metabolic diseases, making it a potential target for therapeutic interventions.

## Interactions
PCYOX1 (prenylcysteine oxidase 1) is involved in several interactions with other proteins, particularly in the context of lipoprotein metabolism and oxidative stress. It is associated with apolipoprotein B (apoB)-enriched lipoproteins, such as VLDL, and plays a role in the oxidative modification of these lipoproteins by generating hydrogen peroxide (H2O2) (Banfi2021Prenylcysteine). This interaction is significant in the context of atherosclerosis, where PCYOX1 is found to associate with nascent apoB100-containing lipoproteins in the endoplasmic reticulum during their biogenesis (Banfi2021Prenylcysteine).

PCYOX1 also interacts with protein disulfide-isomerase A3, an endoplasmic reticulum marker, as shown by immunostaining studies in HepG2 cells (Banfi2021Prenylcysteine). This interaction suggests a role in protein folding and oxidative stress response. The enzyme's association with lipoproteins such as VLDL, LDL, and HDL may influence its catalytic efficiency and role in atherosclerosis (Banfi2021Prenylcysteine).

In the context of adipogenesis, PCYOX1 is involved in the transcriptional regulatory cascade involving C/EBP family members and PPARs, indicating its role in early adipogenesis steps (Banfi2023Prenylcysteine). These interactions highlight PCYOX1's multifaceted role in cellular processes related to lipid metabolism and oxidative stress.


## References


[1. (Banfi2023Prenylcysteine) Cristina Banfi, Alice Mallia, Stefania Ghilardi, Maura Brioschi, Erica Gianazza, Sonia Eligini, Pelin Sahlén, and Roberta Baetta. Prenylcysteine oxidase 1 is a key regulator of adipogenesis. Antioxidants, 12(3):542, February 2023. URL: http://dx.doi.org/10.3390/antiox12030542, doi:10.3390/antiox12030542. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/antiox12030542)

[2. (Banfi2022Prenylcysteine) Cristina Banfi, Patrizia Amadio, Marta Zarà, Maura Brioschi, Leonardo Sandrini, and Silvia S. Barbieri. Prenylcysteine oxidase 1 (pcyox1), a new player in thrombosis. International Journal of Molecular Sciences, 23(5):2831, March 2022. URL: http://dx.doi.org/10.3390/ijms23052831, doi:10.3390/ijms23052831. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms23052831)

[3. (Banfi2021Prenylcysteine) C. Banfi, R. Baetta, S. S. Barbieri, M. Brioschi, A. Guarino, S. Ghilardi, L. Sandrini, S. Eligini, G. Polvani, O. Bergman, P. Eriksson, and E. Tremoli. Prenylcysteine oxidase 1, an emerging player in atherosclerosis. Communications Biology, September 2021. URL: http://dx.doi.org/10.1038/s42003-021-02630-z, doi:10.1038/s42003-021-02630-z. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s42003-021-02630-z)

[4. (Osada2018Prenylcysteine) Jesus Osada. Prenylcysteine oxidase 1 a pro-oxidant enzyme of low density lipoproteins. Frontiers in Bioscience, 23(3):1020–1037, 2018. URL: http://dx.doi.org/10.2741/4631, doi:10.2741/4631. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.2741/4631)